BACKGROUND: The aim of this study was to evaluate the prevalence of chromosome 8q gain in clear cell renal cell carcinoma (CCRCC) and to correlate the findings with tumor phenotype and disease-specific survival (DSS). METHODS: The tumor karyotypes of 336 consecutive patients with CCRCC were prospectively evaluated with classical cytogenetic analysis. Chromosome 8q status was correlated with clinicopathological variables, and its impact on DSS was evaluated. RESULTS: Gain of 8q occurred in 28 tumors (8.3%). Gain of 8q was associated with a higher risk of regional lymph node (21.4% vs 6.2%, P = .011) and distant metastases (50.0% vs 24.4%, P = .006), and greater tumor sizes (P = .030). Patients with gain of 8q had a 3.22-fold increased risk of death from CCRCC (P < .001). In multivariable analysis, gain of 8q was identified as an independent prognostic factor (hazard ratio, 2.37; P = .006). The concordance index of a multivariable base model increased significantly following inclusion of 8q gain (P = .0015). CONCLUSIONS: Gain of chromosome 8q occurs in a subset of CCRCCs and is associated with an increased risk of metastases and death from CCRCC. Because the proto-oncogene c-MYC is among the list of candidate genes located on 8q, our data suggest that these tumors may have unique pathways activated, which are associated with an aggressive tumor phenotype. If confirmed, defining tumors with gain of 8q may assist in identifying patients who would benefit for specific c-MYC inhibitors or agents that target the MAPK/ERK (mitogen-activated protein kinase) pathway.
BACKGROUND: The aim of this study was to evaluate the prevalence of chromosome 8q gain in clear cell renal cell carcinoma (CCRCC) and to correlate the findings with tumor phenotype and disease-specific survival (DSS). METHODS: The tumor karyotypes of 336 consecutive patients with CCRCC were prospectively evaluated with classical cytogenetic analysis. Chromosome 8q status was correlated with clinicopathological variables, and its impact on DSS was evaluated. RESULTS: Gain of 8q occurred in 28 tumors (8.3%). Gain of 8q was associated with a higher risk of regional lymph node (21.4% vs 6.2%, P = .011) and distant metastases (50.0% vs 24.4%, P = .006), and greater tumor sizes (P = .030). Patients with gain of 8q had a 3.22-fold increased risk of death from CCRCC (P < .001). In multivariable analysis, gain of 8q was identified as an independent prognostic factor (hazard ratio, 2.37; P = .006). The concordance index of a multivariable base model increased significantly following inclusion of 8q gain (P = .0015). CONCLUSIONS: Gain of chromosome 8q occurs in a subset of CCRCCs and is associated with an increased risk of metastases and death from CCRCC. Because the proto-oncogene c-MYC is among the list of candidate genes located on 8q, our data suggest that these tumors may have unique pathways activated, which are associated with an aggressive tumor phenotype. If confirmed, defining tumors with gain of 8q may assist in identifying patients who would benefit for specific c-MYC inhibitors or agents that target the MAPK/ERK (mitogen-activated protein kinase) pathway.
Authors: Nicole M White-Al Habeeb; Ashley Di Meo; Andreas Scorilas; Fabio Rotondo; Olena Masui; Annetta Seivwright; Manal Gabril; Andrew H A Girgis; Michael A Jewett; George M Yousef Journal: Clin Exp Metastasis Date: 2015-06-03 Impact factor: 5.150
Authors: Johannes Schödel; Steffen Grampp; Eamonn R Maher; Holger Moch; Peter J Ratcliffe; Paul Russo; David R Mole Journal: Eur Urol Date: 2015-08-19 Impact factor: 20.096
Authors: Brandon John Manley; Emily C Zabor; Jozefina Casuscelli; Daniel M Tennenbaum; Almedina Redzematovic; Maria F Becerra; Nicole Benfante; Yusuke Sato; Teppei Morikawa; Haruki Kume; Masashi Fukayama; Yukio Homma; Seishi Ogawa; Maria E Arcila; Martin H Voss; Darren R Feldman; Jonathan A Coleman; Victor E Reuter; Robert J Motzer; Paul Russo; James J Hsieh; A Ari Hakimi Journal: Eur Urol Focus Date: 2016-07-16
Authors: A Ari Hakimi; Roy Mano; Giovanni Ciriello; Mithat Gonen; Nina Mikkilineni; John P Sfakianos; Philip H Kim; Robert J Motzer; Paul Russo; Victor E Reuter; James J Hsieh; Irina Ostrovnaya Journal: J Urol Date: 2014-02-08 Impact factor: 7.450
Authors: Andres F Correa; Karen J Ruth; Tahseen Al-Saleem; Jianming Pei; Essel Dulaimi; Debra Kister; Michelle Collins; Phillip H Abbosh; Michael J Slifker; Eric Ross; Robert G Uzzo; Joseph R Testa Journal: Cancer Biol Ther Date: 2020-03-01 Impact factor: 4.742
Authors: Timothy Ito; Jianming Pei; Essel Dulaimi; Craig Menges; Philip H Abbosh; Marc C Smaldone; David Y T Chen; Richard E Greenberg; Alexander Kutikov; Rosalia Viterbo; Robert G Uzzo; Joseph R Testa Journal: J Urol Date: 2015-11-18 Impact factor: 7.450